Yves Poulin

Yves Poulin

Auto-generated profile, based on publicly available information

Yves Poulin

Centre de Recherche Dermatologique du Québec Métropolitain, Quebec City, QC, Canada; and Laval University, Quebec City, QC, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SFSeth B. Forman
Seth B. Forman
DPDavid M. Pariser
David M. Pariser
YPYves Poulin
Yves Poulin
MVMichael S. Vincent
Michael S. Vincent
SGSteven A. Gilbert
Steven A. Gilbert
EPElena Peeva
Elena Peeva

5 June 2020 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
PDF file
JYJensen Yeung
Jensen Yeung
MGMelinda Gooderham
Melinda Gooderham
PGParbeer Grewal
Parbeer Grewal
CHChih-Ho Hong
Chih-Ho Hong
PLPerla Lansang
Perla Lansang
RVRonald Vender
Ronald Vender
Background: Plaque psoriasis (PsO) is a chronic inflammatory disease that often presents at peak reproductive age in women of child-bearing potential (WOCBP). With the emergence of biologic therapies to treat PsO, guidance on disease management in WOCBP is needed to inform treatment decisions before, during, and after pregnancy. Objectives: To develop a practical, up-to-date consensus document, based on available evidence and expert opinion where evidence was lacking, in order to guide both Canadian and international clinicians treating PsO in WOCBP. Methods: A panel of 9 Canadian dermatologists with extensive clinical experience managing PsO reviewed the relevant literature from the past 25 years in 3 key domains: overview of PsO in WOCBP and clinical considerations, treatment considerations, and postpartum considerations. The structured literature search focused on WOCBP treated with TNF-alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), IL-12/23 inhibitors (ustekinumab), and IL-17 inhibitors (brodalumab, ixekizumab, secukinumab). This literature review, along with clinical expertise and opinion, was used to develop concise and clinically relevant consensus statements to guide practical management of PsO in WOCBP. Experts voted on the statements using a modified Delphi process and prespecified agreement cut-off of 75%. Results and implications: After review, discussion, and voting on 19 draft consensus statements at an in-person meeting and remotely, 12 consensus statements were approved by the expert panel. The statements presented here will guide healthcare providers in practical disease management using biologic therapies for the treatment of PsO in WOCBP.

1 July 2010 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
KPKim Papp
Kim Papp
FVFernando Valenzuela
Fernando Valenzuela
YPYves Poulin
Yves Poulin
GBGeula Bernstein
Geula Bernstein
NWNorman Wasel
Norman Wasel
Background: Limited data are available on the epidemiologic features of psoriasis in Canada. Objective: To investigate the epidemiologic features and burden of moderate-to-severe psoriasis in a Canadian population. Methods: An online survey was conducted using a consumer panel. Eligible respondents indicated a diagnosis of psoriasis and plaque-type psoriasis of at least moderate severity. Eligibility was validated according to self-reported body surface area (BSA) involvement, sensitive areas affected, and/or current treatment. Results: Of the 514 respondents who completed the survey, 62% estimated a BSA involvement of ≥ 3% within the past 5 years. Onset of psoriasis occurred earlier in females than in males. Nail involvement was more commonly reported in individuals with psoriatic arthritis compared to those without. Several symptoms were more likely described as “constantly” or “near constantly” experienced by females than by males. Comorbidities commonly reported were hypertension, dyslipidemia, and overweight or obesity. Conclusions: The findings are consistent with a substantial burden attributed to moderate-to-severe plaque psoriasis in a Canadian population.

29 June 2020 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
PDF file
YPYves Poulin
Yves Poulin
CBCatherine Beauchemin
Catherine Beauchemin
CRCatherine Royer
Catherine Royer
AGAnne-Julie Gaudreau
Anne-Julie Gaudreau
CYClarabella Yim
Clarabella Yim
JLJean Lachaine
Jean Lachaine
In Québec, targeted biologic therapies for moderate to severe plaque psoriasis are restricted to patients who have not responded to phototherapy or conventional systemic treatment, primarily due to high drug costs. Apremilast, an oral treatment for plaque psoriasis, was added to the Québec provincial health insurance plan (Régie de l’assurance maladie du Québec; RAMQ) formulary in 2015, making this the only province in Canada with public drug plan reimbursement for apremilast. The aim of this study is to describe patients’ characteristics, treatment patterns, healthcare resource utilization (HCRU), and associated costs and to measure real-world budget impact of using apremilast before biologics in plaque psoriasis. This study was performed using RAMQ drug claims and medical services data. Patients diagnosed with psoriasis between January 2015 and December 2017 were identified. Medical services and prescription claims were categorized as all-cause and psoriasis-related. Using RAMQ database estimates, a 3-year budget impact analysis was developed comparing treatment cost with and without the addition of apremilast to the formulary. In all, 540 patients were identified (apremilast: n = 92; biologics: n = 448). Comorbidity burden and treatment persistence and adherence were comparable between apremilast and biologic users. The year following the index date, all-cause HCRU was lower for apremilast versus biologic users (CAN$19 763 vs CAN$28 025; P < .01), mainly driven by drug cost. Using apremilast before biologics resulted in an estimated RAMQ net savings of CAN$49 290 (2015), CAN$746 856 (2016), and CAN$1 216 512 (2017), and a total savings of CAN$2 012 658 since apremilast’s addition to the formulary. Adding apremilast to the drug formulary of other Canadian provinces could result in significant healthcare savings.